Reading time is 2 mins


A new method, described as a turning point, can correct as many as 75 thousand harmful gene changes. According to the first trials, scientists performed 175 successful gene changes.

Scientists who invented a powerful new molecular tool that corrects the vast majority of mutations that cause genetic diseases in humans have created hope for the treatment of genetic disorders, according to information from BBC.

The new procedure has the ability to correct about 89 percent of the 75 thousand or so harmful gene mutations that lead to many diseases such as cystic fibrosis, sickle cell anemia, and which destroy nerves.

The study, described as a turning point, opens the door to a new era of genome editing. But the researchers note that more research is needed before the procedure can be safely used in humans.

Another obstacle is ensuring that the molecular tool can be sent in sufficient quantities to the cells involved to treat a disorder.

Important study from Turkish scientists: genetic causes of heart rhythm disorder were determined important study from Turkish scientists: genetic causes of heart rhythm disorder were determined


In the new method developed by scientists, the main regulator contains a protein designed to guide it to its target. The regulator uses an enzyme called cas9 to open the relevant DNA chain when it reaches the target, producing new DNA that will be added to the region in the second step.

Another guiding protein sends the main regulator to the as-yet unregulated opposite side of the DNA chain. The chain of cells re-repairs the edited DNA after copying and inserting it.


The ability to rewrite the genetic code is one of the most striking scientific developments in recent years. Instead of the method that divides the DNA chain in half, the procedure writes a new DNA to the corresponding sequence by “creating a notch” the chain.

The paper, published in the journal Nature, detailed how they performed 175 effective gene changes in human cells using the new method.

Before the new method was developed, it was not possible to make such a variety of DNA changes in different types of cells without adding or releasing other genetic residues that could interfere with the functioning of the regulated cell.


Follow me
President of Organ Transplant Center at MedicalPark Hospital Antalya

Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.

Physician's Resume:

Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.

Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.

In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.


Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.


Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .

Professional Members:

American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.


Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Medically Reviewed by Professor Doctor Alper Demirbaş
Follow me